| Literature DB >> 29159094 |
Yanyan Hu1,2, Jinbo Chen1,3, Lu Yang1, Pin Chen1,4, Juhong Li5, Lin Chen5, Jin Chen1, Xiangqin Huang1,6, Yaping Zhang1, Shizhong Bu7,8, Qin Huang1.
Abstract
AIMS: To analyze the correlation between neck circumference (NC) and non-alcoholic fatty liver disease (NAFLD) and compare the predictive value of NC for NAFLD with that of other simple anthropometric measures and other biochemical profiles.Entities:
Keywords: ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; AUC, Area under the curve; BMI, Body mass index; BUN, Blood urea nitrogen; CVD, Cardiovascular diseases; FBG, Fasting blood glucose; FINS, Fasting insulin; FT3, Free triiodothyronine 3; FT4, Free thyroxine; HC, Hip circumference; HDL-C, High-density lipoprotein cholesterol; HOMA-IR, Homeostasis model assessment-insulin resistance; HUA, Hyperuricemia; HbA1c, Hemoglobin A1c; IR, Insulin resistance; Insulin resistance; LDL-C, Low-density lipoprotein cholesterol; MS, Metabolic syndrome; NAFLD, Nonalcoholic fatty liver disease; NC, Neck circumference; NHtR, Neck circumference-height ratio; NWtR, Neck circumference-weight ratio; Neck circumference; Non-alcoholic fatty liver disease; OR, Odd ratio; QUICKI, Quantitative insulin-sensitivity check index; SUA, Serum uric acid; Scr, Serum creatinine; T2DM, Type 2 diabetes mellitus; TC, Total cholesterol; TG, Triglyceride; TSH, Thyroid stimulating hormone; VAT, Visceral adipose tissue; WC, Waist circumference; Waist circumference; γ-GT, gamma-glutamyltransferase
Year: 2014 PMID: 29159094 PMCID: PMC5685024 DOI: 10.1016/j.jcte.2014.07.001
Source DB: PubMed Journal: J Clin Transl Endocrinol ISSN: 2214-6237
Comparison of clinical features and biochemical criterion between each group
| Clinical indexes | Group A | Group B1 | Group B2 | Group C | |
|---|---|---|---|---|---|
| Case ( | 623 (22.56%) | 697 (25.24%) | 270 (9.78%) | 1171 (42.41%) | |
| M:F | 183:440 | 463:234 | 231:39 | 703:468 | <0.001 |
| Age (year) | 36.70 ± 11.82 | 48.97 ± 12.09 | 42.07 ± 12.01 | 45.29 ± 14.75 | <0.001 |
| Weight (kg) | 56.21 ± 7.31 | 72.73 ± 10.50 | 79.56 ± 11.71 | 65.44 ± 10.16 | <0.001 |
| M | 62.49 ± 7.06 | 76.89 ± 8.96 | 81.20 ± 11.09 | 70.11 ± 8.74 | <0.001 |
| F | 53.59 ± 5.62 | 64.43 ± 8.17 | 69.91 ± 10.65 | 58.40 ± 7.84 | <0.001 |
| BMI (kg/m2) | 20.92 ± 1.84 | 26.29 ± 2.83 | 27.70 ± 3.27 | 23.77 ± 2.65 | <0.001 |
| NC (cm) | 32.60 ± 2.37 | 37.21 ± 3.06 | 38.94 ± 2.62 | 35.33 ± 3.03 | <0.001 |
| M | 35.34 ± 1.90 | 38.75 ± 2.17 | 39.46 ± 2.20 | 37.11 ± 2.09 | <0.001 |
| F | 31.46 ± 1.42 | 34.17 ± 2.15 | 35.86 ± 2.78 | 32.65 ± 2.12 | <0.001 |
| NHtR | 0.20 ± 0.01 | 0.22 ± 0.02 | 0.23 ± 0.01 | 0.21 ± 0.02 | <0.001 |
| M | 0.21 ± 0.01 | 0.23 ± 0.01 | 0.23 ± 0.01 | 0.22 ± 0.01 | <0.001 |
| F | 0.19 ± 0.01 | 0.22 ± 0.01 | 0.23 ± 0.02 | 0.21 ± 0.01 | <0.001 |
| NWtR | 0.59 ± 0.05 | 0.52 ± 0.05 | 0.50 ± 0.06 | 0.54 ± 0.06 | <0.001 |
| M | 0.57 ± 0.05 | 0.51 ± 0.05 | 0.49 ± 0.05 | 0.54 ± 0.05 | <0.001 |
| F | 0.59 ± 0.05 | 0.54 ± 0.05 | 0.53 ± 0.05 | 0.57 ± 0.06 | <0.001 |
| WC (cm) M | 77.78 ± 6.63 | 93.44 ± 7.50 | 96.34 ± 7.51 | 85.74 ± 7.59 | <0.001 |
| F | 71.40 ± 5.52 | 85.47 ± 7.74 | 90.14 ± 9.47 | 78.38 ± 7.74 | <0.001 |
| WHR | 0.79 ± 0.06 | 0.92 ± 0.07 | 0.94 ± 0.06 | 0.86 ± 0.07 | <0.001 |
| M | 0.83 ± 0.06 | 0.93 ± 0.06 | 0.95 ± 0.05 | 0.88 ± 0.06 | <0.001 |
| F | 0.77 ± 0.05 | 0.88 ± 0.06 | 0.91 ± 0.06 | 0.83 ± 0.06 | <0.001 |
| ALT (U/L) | 15.65 ± 10.77 | 24.22 ± 7.95 | 66.26 ± 30.16 | 21.38 ± 12.19 | <0.001 |
| HbA1c (%) | 5.23 ± 0.53 | 5.58 ± 1.08 | 6.18 ± 1.36 | 5.44 ± 0.76 | <0.001 |
| FINS (μIU/ml) | 18.68 ± 8.43 | 26.51 ± 13.59 | 33.7 ± 19.17 | 20.92 ± 9.31 | <0.001 |
| FCP (ng/ml) | 2.55 ± 0.93 | 3.79 ± 1.43 | 4.51 ± 1.62 | 3.01 ± 1.25 | <0.001 |
| HOMA-IR | 1.18 ± 1.99 | 6.85 ± 5.12 | 9.17 ± 7.50 | 5.05 ± 3.07 | <0.001 |
| QUICKI | 1.15 ± 0.13 | 0.98 ± 0.14 | 0.91 ± 0.15 | 1.08 ± 0.14 | <0.001 |
Group A, healthy subjects; Group B, NAFLD subjects; Group B1, subjects without elevated ALT; Group B2, subjects with elevated ALT; Group C, subjects with other metabolic disturbances.
Differences are statistically significant between each group in four groups (P < 0.05).
Differences are no statistically significant between group B1 and B2 (P > 0.05).
Correlational analysis between body measurements and FINS, HOMA-IR
| Variables | Lg (FINS) | Lg (HOMA-IR) | ||||||
|---|---|---|---|---|---|---|---|---|
| Male | Female | Male | Female | |||||
| NC (cm) | 0.250 | <0.001 | 0.345 | <0.001 | 0.250 | <0.001 | 0.339 | <0.001 |
| WC (cm) | 0.351 | <0.001 | 0.282 | <0.001 | 0.325 | <0.001 | 0.314 | <0.001 |
| BMI (kg/m2) | 0.303 | <0.001 | 0.318 | <0.001 | 0.270 | <0.001 | 0.298 | <0.001 |
| NHtR | 0.166 | <0.001 | 0.322 | <0.001 | 0.165 | <0.001 | 0.294 | <0.001 |
| NWtR | −0.282 | <0.001 | −0.121 | 0.073 | −0.243 | <0.001 | −0.147 | 0.029 |
| WHR | 0.262 | <0.001 | 0.207 | 0.002 | 0.260 | <0.001 | 0.291 | <0.001 |
| Wt (kg) | 0.338 | <0.001 | 0.266 | <0.001 | 0.307 | <0.001 | 0.281 | <0.001 |
Risk factors of NAFLD by logistic regression analysis
| Risk factors | Wald | OR-value | 95% CI of OR | |||
|---|---|---|---|---|---|---|
| Upper limit | Lower limit | |||||
| NAFLD | ||||||
| NC | −0.369 | 3.748 | 0.053 | 0.691 | 0.476 | 1.005 |
| NHtR | 1.124 | 54.903 | <0.001 | 3.078 | 2.286 | 4.144 |
| NWtR | −0.942 | 101.916 | <0.001 | 0.390 | 0.325 | 0.468 |
| WHR | 0.647 | 52.313 | <0.001 | 1.910 | 1.603 | 2.276 |
| NAFLD without elevated ALT | ||||||
| NHtR | 0.490 | 45.717 | <0.001 | 1.632 | 1.416 | 1.882 |
| NWtR | −0.479 | 44.977 | <0.001 | 0.619 | 0.538 | 0.712 |
| WHR | 0.315 | 13.526 | <0.001 | 1.371 | 1.159 | 1.621 |
| NAFLD with elevated ALT | ||||||
| NHtR | 0.543 | 24.273 | <0.001 | 1.721 | 1.387 | 2.136 |
| NWtR | −0.499 | 16.361 | <0.001 | 0.607 | 0.477 | 0.773 |
| WHR | 0.549 | 15.993 | <0.001 | 1.731 | 1.323 | 2.265 |
Comparison of NAFLD prevalence in different NC groups
| NC | Non-abdominal obesity | Abdominal obesity | ||
|---|---|---|---|---|
| Cases ( | Prevalence (%) | Cases ( | Prevalence (%) | |
| <P25 | 70 | 9.41 (70/744) | 18 | 51.43 (18/35) |
| P25–P50 | 122 | 19.03 (122/641) | 110 | 58.20 (110/189) |
| P50–P75 | 96 | 29.81 (96/322) | 137 | 62.56 (137/219) |
| >75 | 52 | 37.41 (52/139) | 362 | 76.69 (362/472) |
| Total | 340 | 18.42 (340/1846) | 627 | 68.52 (627/915) |
P, percentage.
Analytical between NAFLD prevalence and body measurements
| Body measurements | Non-abdominal obesity | Abdominal obesity | ||
|---|---|---|---|---|
| Cases ( | Prevalence (%) | Cases ( | Prevalence (%) | |
| NC (cm) | ||||
| Male | ||||
| <38.51 | 166 | 20.62 (166/805) | 143 | 62.72 (143/228) |
| ≥38.51 | 55 | 45.45 (55/121)** | 330 | 77.46 (330/426)** |
| Female | ||||
| <33.80 | 67 | 8.69 (67/771) | 42 | 48.28 (42/87) |
| ≥33.80 | 52 | 34.90 (52/149)** | 112 | 64.37 (112/174)* |
| NHtR | ||||
| Male | ||||
| <0.23 | 163 | 20.3 (163/803) | 215 | 63.8 (215/337) |
| ≥0.23 | 57 | 47.5 (57/120)** | 256 | 81.3 (256/315)** |
| Female | ||||
| <0.22 | 90 | 10.5 (90/858) | 76 | 53.5 (76/142) |
| ≥0.22 | 28 | 49.1 (28/57)** | 77 | 67.0 (77/115)* |
| NWtR | ||||
| Male | ||||
| >0.49 | 189 | 22.9 (189/829) | 225 | 69.2 (225/325) |
| ≤0.49 | 31 | 32.0 (31/97)* | 246 | 75.2 (246/327) |
| Female | ||||
| >0.51 | 100 | 11.9 (100/843) | 84 | 53.8 (84/156) |
| ≤0.51 | 18 | 25.0 (18/72)** | 69 | 68.3 (69/101)* |
vs normal values of same sex.
* P < 0.05, **P < 0.001.
Figure 1Receiver Operating Characteristic (ROC) curve of NC and NHtR in distinguishing NAFLD or Non-NAFLD in different sex.